CardioVia Secures Medical Device Patents in Major Markets

December 2024

CardioVia Strengthens IP Portfolio with Medical Device Patents in Major Markets

CardioVia was granted broad patent protection across the United States, Europe, Israel, Japan and China for its unique blunt-tip concealed needle and bio-impedance navigation system. This strong IP portfolio secures ViaOne’s leadership position while protecting future applications such as drug delivery, pacemaker implantation, and advanced cardiac therapies.

The newly granted medical device patents further reinforce CardioVia’s leadership in the field of minimally invasive cardiac access. By securing exclusive rights in key territories, the company ensures global protection of its proprietary ViaOne™ technology—an innovation designed to enable safe, controlled access to the heart’s surface without an exposed needle.

These medical device patents form the foundation for CardioVia’s continued expansion into new indications and product extensions that could reshape epicardial access and therapeutic delivery. The intellectual property protection also supports ongoing collaborations with clinical and commercial partners worldwide.

“Expanding our medical device patents portfolio is a critical step in safeguarding CardioVia’s technology and enabling long-term innovation,” said Ziv Menshes, CEO of CardioVia. “This strengthens our ability to bring next-generation cardiac solutions to patients globally.”

With patents now issued in all major regions, CardioVia is positioned to accelerate commercialization and development of future minimally invasive cardiac platforms.